ASLAN Pharmaceuticals (ASLN) Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis

ASLAN Pharmaceuticals (ASLN) Prices 75M Share Common Offering at $4/Sh

ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the pricing of an underwritten public offering of 15,000,000 American Depositary Shares (ADSs) representing 75,000,000 ordinary shares at a price to the public of $4.00 per ADS. The gross proceeds from this offering are expected to... More